COMPANY PROFILE

Hummingbird Bioscience

Explore full profile

Hummingbird Bioscience is an innovative therapeutics company

Singapore, SingaporeFounded 2015Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2021

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Hummingbird Bioscience

Hummingbird Bioscience is a biotechnology startup that operates in the healthcare sector, specifically in the development of precision biotherapeutics. The company's primary focus is on creating innovative treatments for cancer and autoimmune diseases. These are areas of medicine where current treatments often fall short, and Hummingbird Bioscience aims to fill this gap by targeting biologically validated but previously undruggable targets.

The company's business model revolves around its proprietary Rational Antibody Discovery platform. This platform uses a data-driven systems biology approach to engineer and develop next-generation therapies. In simpler terms, they use a combination of biology, data analysis, and technology to create new, more precise treatments for diseases.

Hummingbird Bioscience makes money by developing these new treatments and bringing them to market. They also use biomarker-driven clinical trials to increase the chances of successful clinical development. Biomarkers are substances in the body that can be measured to indicate the presence or severity of a disease. By focusing on these biomarkers, Hummingbird Bioscience can more accurately determine the effectiveness of their treatments.

The company serves a broad range of clients, including patients who do not respond to current treatments, healthcare providers looking for more effective therapies, and other stakeholders in the healthcare sector.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Singapore, Singapore
Employees: 84
Open positions: 3
Dealroom signal: 83.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Core AI, Biotech and Pharma, Hard Tech, AI Applications, DT and LS, science-based
Technology: Artificial Intelligence
Business model: Manufacturing
Client focus: b2b
Investment activity: 1 company, latest Mar 2025
Capital deployed: $67M
Preferred round: SERIES A
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES COther financing	May 2021	$125M	$500M	Polaris Partners · Mirae Asset Venture Investment · SK Group · Frazier Healthcare Partners	↗
SERIES BOther financing	May 2020	$0	—	Heritas Capital Management	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Hummingbird Bioscience website traffic

Latest recorded traffic for Hummingbird Bioscience is 4.6K monthly website visits, down 49.5% over the last three months. Hummingbird Bioscience's team grew 2.4% over the past year.

Latest monthly visits4.6K 3-month web change-49.5% 1-year team growth+2.4%

Monthly website visitsDec 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Intern, IT OperationsSingapore, Singapore, South-eastern Asia, Asia · Human Resources · Aug 21, 2026 Research Scientist / Senior Research Associate , Immunoassay and Cell BiologySingapore, Singapore, South-eastern Asia, Asia · Other · Jun 26, 2026

2 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PHPhaseVUses advanced algorithms to optimize clinical trials, improving success rates, efficiency, and uncovering hidden signals in the data	Tel Aviv-Yafo, Israel	Operational	71	$65M	$200M
CTCeleris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases	Graz, Austria	Operational
EXExogeneBiotechnology company accelerating target and TCR discovery for cancer cell therapies using AI-enabled TCR-antigen screening	Oxford, United Kingdom	Operational
LFLazarus FormsLazarus - AI for Cancer Detection	Cambridge, United States	Operational
DSDeep Trait S.A.Biotechnology company with a mission to address fundamental questions of food supply, health care and life itself with artificial intelligence	Aschersleben, Germany	Operational
OMOnconano MedicineDeveloping a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease	Southlake, United States	Operational
CSCaris Life SciencesA profiling platform that identifies novel molecular targets to inform and enhance drug development and advanced diagnostics	Irving, United States	Operational
APA2A PharmaceuticalsBiotechnology company committed to the advancement of innovative scientific research and new therapeutic agents	New York City, United States	Operational